Polymorphisms of norepinephrine transporter and adrenergic receptor α1D are associated with the response to β-blockers in dilated cardiomyopathy

[1]  Julie A. Johnson,et al.  Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.

[2]  H. Nakano,et al.  Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment , 2005, Nuclear medicine communications.

[3]  M. Iyo,et al.  Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder , 2005, The Pharmacogenomics Journal.

[4]  H. Kroemer,et al.  CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects , 2004, Clinical pharmacology and therapeutics.

[5]  S. Hosoda,et al.  Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. , 2004, American heart journal.

[6]  S. Coca,et al.  COMET: a proposed mechanism of action to explain the results and concerns about dose , 2003, The Lancet.

[7]  G. Dorn,et al.  β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.

[8]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[9]  G. Jennings,et al.  Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. , 2003, Pharmacogenetics.

[10]  G. Tsujimoto,et al.  Differential Cardiovascular Regulatory Activities of the α1B- and α1D-Adrenoceptor Subtypes , 2003, Journal of Pharmacology and Experimental Therapeutics.

[11]  G. Tsujimoto,et al.  Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes. , 2003, The Journal of pharmacology and experimental therapeutics.

[12]  G. Tsujimoto,et al.  Role of the α1D-Adrenegric Receptor in the Development of Salt-Induced Hypertension , 2002 .

[13]  G. Eisenhofer.  The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, Pharmacology & therapeutics.

[14]  S. Liggett,et al.  A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human α2C-Adrenergic Receptor Confers Impaired Coupling to Multiple Effectors* , 2000, The Journal of Biological Chemistry.

[15]  M. Laakso,et al.  Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[17]  M. Lai,et al.  Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes , 1999, Clinical pharmacology and therapeutics.

[18]  F. Follath,et al.  Etiology and response to drug treatment in heart failure. , 1998, Journal of the American College of Cardiology.

[19]  Britton,et al.  β2‐adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[20]  C. Visser,et al.  Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. , 1998, Journal of cardiovascular pharmacology.

[21]  I. Narabayashi,et al.  Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. , 1997, American heart journal.

[22]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[23]  G. Tucker,et al.  Oxidation phenotype--a major determinant of metoprolol metabolism and response. , 1982, The New England journal of medicine.